Medigene Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Medigene has been growing earnings at an average annual rate of 11.2%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 7.5% per year.
Belangrijke informatie
11.2%
Groei van de winst
11.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | -14.6% |
Inkomstengroei | 7.5% |
Rendement op eigen vermogen | -81.0% |
Nettomarge | -214.0% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation
Jan 03The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business
Aug 12Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%
Aug 10We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely
Mar 24Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation
Nov 29This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO
Jun 17We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate
Mar 29How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 16How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?
Dec 23Opbrengsten en kosten
Hoe Medigene geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 7 | -16 | 9 | 13 |
31 Mar 24 | 7 | -16 | 9 | 12 |
31 Dec 23 | 6 | -16 | 9 | 12 |
30 Sep 23 | 8 | -23 | 9 | 11 |
30 Jun 23 | 9 | -29 | 8 | 10 |
31 Mar 23 | 20 | -19 | 9 | 9 |
31 Dec 22 | 31 | -8 | 10 | 8 |
30 Sep 22 | 31 | 1 | 10 | 8 |
30 Jun 22 | 31 | 10 | 10 | 9 |
31 Mar 22 | 21 | 0 | 8 | 10 |
31 Dec 21 | 10 | -10 | 7 | 11 |
30 Sep 21 | 10 | -16 | 7 | 14 |
30 Jun 21 | 9 | -22 | 7 | 17 |
31 Mar 21 | 8 | -25 | 8 | 20 |
31 Dec 20 | 8 | -29 | 9 | 22 |
30 Sep 20 | 9 | -25 | 9 | 23 |
30 Jun 20 | 9 | -23 | 8 | 23 |
31 Mar 20 | 10 | -21 | 8 | 23 |
31 Dec 19 | 11 | -20 | 8 | 23 |
30 Sep 19 | 9 | -23 | 8 | 20 |
30 Jun 19 | 9 | -23 | 8 | 19 |
31 Mar 19 | 8 | -19 | 8 | 18 |
31 Dec 18 | 8 | -21 | 8 | 17 |
30 Sep 18 | 8 | -18 | 8 | 17 |
30 Jun 18 | 8 | -16 | 7 | 16 |
31 Mar 18 | 8 | -16 | 8 | 16 |
31 Dec 17 | 8 | -16 | 8 | 15 |
30 Sep 17 | 8 | -14 | 9 | 15 |
30 Jun 17 | 8 | -17 | 10 | 14 |
31 Mar 17 | 8 | -12 | 10 | 13 |
31 Dec 16 | 7 | -9 | 10 | 12 |
30 Sep 16 | 6 | -8 | 10 | 10 |
30 Jun 16 | 7 | -7 | 8 | 9 |
31 Mar 16 | 7 | -11 | 8 | 9 |
31 Dec 15 | 7 | -13 | 8 | 9 |
30 Sep 15 | 11 | -11 | 7 | 8 |
30 Jun 15 | 11 | -9 | 7 | 8 |
31 Mar 15 | 13 | -7 | 7 | 8 |
31 Dec 14 | 13 | -6 | 7 | 7 |
30 Sep 14 | 10 | -8 | 8 | 7 |
30 Jun 14 | 9 | -7 | 8 | 7 |
31 Mar 14 | 8 | -9 | 8 | 6 |
31 Dec 13 | 8 | -10 | 8 | 7 |
Kwaliteitswinsten: MDG1 is currently unprofitable.
Groeiende winstmarge: MDG1 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: MDG1 is unprofitable, but has reduced losses over the past 5 years at a rate of 11.2% per year.
Versnelling van de groei: Unable to compare MDG1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: MDG1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: MDG1 has a negative Return on Equity (-81.04%), as it is currently unprofitable.